Allurion announces new strategic direction with increasing focus on low-dose glp-1 combination therapy, muscle mass maintenance, and us market entry

Natick, mass.--(business wire)---- $alur--allurion technologies, inc. (nyse: alur), a pioneer in metabolically healthy weight loss, today announced a new strategic direction with an increasing focus on low-dose glp-1 combination therapy, muscle mass maintenance, and us market entry. the company has reported on real-world data from nearly 20,000 patients that demonstrate that patients using the allurion program lose weight immediately and through a focus on behavior change, keep the weight off while incre.
ALUR Ratings Summary
ALUR Quant Ranking